COVID-19 and immunomodulation treatment for women with reproductive failures

COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak-Kim, Joanne, Ota, Kuniaki, Sung, Nayoung, Huang, Changsheng, Alsubki, Lujain, Lee, Sungki, Han, Jae Won, Han, Aera, Yang, Xiuhua, Saab, Wael, Derbala, Youssef, Wang, Wen-Juan, He, Qiaohua, Liao, Aihua, Takahashi, Toshifumi, Cavalcante, Marcelo Borges, Barini, Ricardo, Bao, Shihua, Fukui, Atsushi, Lédée, Nathalie, Coulam, Carolyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291967/
https://www.ncbi.nlm.nih.gov/pubmed/32603991
http://dx.doi.org/10.1016/j.jri.2020.103168
Descripción
Sumario:COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. Many questions have been raised for women with immunotherapy during the COVID-19 pandemic, including infection susceptibility, how to manage women with an increased risk of and active COVID-19 infection. SARS-CoV-2 is a novel virus, and not enough information exists. Yet, we aim to review the data from previous coronavirus outbreaks and current COVID-19 and provide interim guidelines for immunotherapy in women with reproductive failures.

Ejemplares similares